Oral Bioequivalence Study of PL 3100 and Naproxen in Healthy Adults
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the single-dose pharmacokinetics of the
investigational drug PL 3100 following oral administration to healthy volunteers and to
compare the pharmacokinetic profiles of PL 3100 and naproxen at a prescription dose.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
PLx Pharma
Collaborator:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)